Pricing Log in Create free account
Saturday 31 October 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024. In the quarter to June 2026, revenue grew 47.7%, EPS grew 26.2%, free cash flow grew 458.1% and total debt rose 37.6%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for five.

1,415.16 41.46 +3.02%
Market cap
$1.29T
P/E
47.5×
Fwd P/E
36.7×
Dividend yield
0.47%
F-score
7/9
Altman Z
8.61
Beneish M
−1.91
Dividend safety
86/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Eli Lilly and Company 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 11:35 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 5, 2026: 2 removed · 22 modified; 8 with only figures updated; 1 moved without change

  1. Modified · Financial Results

    Net income and earnings per share for the three months ended June 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, asset impairment, restructuring, and other special charges, and marketing, selling, and administrative expenses. Net income and earnings per share for the six nine months ended JuneSeptember 30, 2026 increased primarily due to higher gross margin, partially offset by higher acquired IPR&D charges, research and development expenses, and marketing, selling, and administrative expenses.

23 more changes in this Item, word by word, in Powerpack.